INS and metabolic dysfunction-associated steatohepatitis: Currently, there is still a lack of drugs that are approved by the Food and Drug Administration (FDA) to treat NAFLD/NASH, but some pharmacological agents, such as insulin sensitizers, antioxidants, lipotoxicity-based targets, gastrointestinal hormones and molecules that modulate nuclear transcription factors, have been considered to be alternative therapeutics (Raza et al., 2021).